Ameet Mallik is the Chief Executive Officer of ADC Therapeutics, a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation targeted antibody drug conjugates. Mr. Mallik has over 25 years of pharmaceutical industry experience, including prior leadership roles at Rafael Holdings and Novartis. He currently serves on the Boards of ADC Therapeutics and Atara Biotherapeutics. He holds an MBA from The Wharton School at the University of Pennsylvania and earned his M.S. in Biotechnology and B.S. in Chemical Engineering from Northwestern University.
People are living longer and this growing patient population needs innovative treatments tailored to the needs of aging bodies, which is why clinical research must include elderly patients.